Research Article
PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma
Table 1
Relation of the characteristics in 87 NDMM patients.
| | Characteristic | No. of patient/total no. (%) | 0 & + () | ++ & +++ () | value |
| | 28/87 (32) | 16/43 (37) | 12/44 (27) | 0.321† | | Male sex | 44/87 (50) | 26/43 (60) | 18/44 (40) | 0.068† | | 70/87 (80) | 29/43 (67) | 41/44 (93) | 0.002† | | 19/87 (21) | 13/43 (30) | 6/44 (13) | 0.073 | | 30/87 (34) | 8/43 (18) | 22/44 (50) | 0.002† | | 27/87 (31) | 15/43 (34) | 12/44 (27) | 0.492 | | 40/87 (45) | 18/43 (41) | 22/44 (50) | 0.521 | | 34/87 (39) | 17/43 (39) | 17/44 (38) | 0.931† | | 35/87 (40) | 16/43 (37) | 19/44 (43) | 0.663 |
|
|
Abbreviations: sCr: serum creatinine; CRP: C-reactive protein; ESR: erythrocyte sedimentation; ALB: serum albumin; β2-MG: β2-microglobulin; LDH: lactate dehydrogenase. Fisher’s exact test was used. †The chi-square test was used. |
